ERBB3 and head and neck squamous cell carcinoma: This phase II study evaluated the efficacy of duligotuzumab vs. cetuximab in patients with R/M SCCHN progressive on/after chemotherapy and included post hoc analyses by NRG1 expression levels, ERBB3 expression levels, and human papillomavirus (HPV) status.